A Prospective Open Labelled Phase-II Non Randomized Clinical Trial on Jaathipalathi Chooranam for the treatment of Swasakasam (Bronchial Asthma)

Increasing prevalence of the respiratory diseases are reporting both in developed and developing countries. On comparing the symptoms of “Swasakasam” it can be correlated to “Bronchial asthma” in modern science.40 patients (20-out patients and 20-in patients) were selected for the study conducted in GSMC& H, Palayamkottai.Trial medicine Jaathipalathi Chooranam 30 mg/ kg /BW thrice a day, after food along with honey for 30 days was administrated for entire study period. Jaathipalathi Chooranam has the reference from Sarabendhra Vaithiya Muraikal-Kasa Swasa Roga Sikicha, Vasudevasasthri, and Venkadarajan,2006. Trial medicine was subjected to various pre-clinical studies like bio- chemical, phytochemical, pharmacological and microbiological analysis. Safety profile of the trial drug was evaluated and no morbidity and mortality was noted in experimental analysis. The biochemistry analysis showed, the presence of Calcium, Starch, Ferrous iron, Tannic acid Unsaturated compound, Reducing sugar and aminoacid. The alkaloids, Carbohydrates, Glycosides, Phytosterols, Flavonoids, Tannin, Protien and Lignin were observed in Phytochemical analysis. Invivo and Invitro studies are showed the better results in Antihistaminic and Anti anaphylactic, Antiinflammotary and Bronchodilator activity. The trial medicine was found to have high sensitivity in Staphylococcus aureus, Streptococcus mutans, Bacillus subtilis, Klebsiella pneumoniae and E.coli organism. At the end of the study majority of the cases were analysed with fixed clinical criterias and showed good clinical improvement. All the relevant reports were statistically analysed and found to be significant